TEV-289

TEV-289 is a biosimilar drug candidate currently in the preclinical stage of development by Teva Pharmaceuticals. It is part of Teva's strategic "Pivot to Growth" initiative, which focuses on expanding the company's biosimilar portfolio to include high-value biologic products in therapeutic areas such as oncology and immunology. As of early 2024, the specific reference biologic and molecular target for TEV-289 have not been publicly disclosed by Teva, although industry reports frequently associate the program with major immune checkpoint inhibitors facing patent expiration in the late 2020s. The development of TEV-289 reflects Teva's commitment to strengthening its presence in the complex generics and biosimilars market to provide more affordable access to critical biologic therapies.